BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19698954)

  • 1. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.
    Antzelevitch C; Burashnikov A
    J Electrocardiol; 2009; 42(6):543-8. PubMed ID: 19698954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial-selective sodium channel blockers: do they exist?
    Burashnikov A; Antzelevitch C
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):121-8. PubMed ID: 18670368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
    Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
    Ann N Y Acad Sci; 2008 Mar; 1123():105-12. PubMed ID: 18375582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.
    Antzelevitch C; Burashnikov A
    Ann N Y Acad Sci; 2010 Feb; 1188():78-86. PubMed ID: 20201889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.
    Burashnikov A; Belardinelli L; Antzelevitch C
    J Pharmacol Exp Ther; 2012 Jan; 340(1):161-8. PubMed ID: 22005044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
    Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
    Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.
    Burashnikov A; Di Diego JM; Barajas-Martínez H; Hu D; Cordeiro JM; Moise NS; Kornreich BG; Belardinelli L; Antzelevitch C
    Circ Heart Fail; 2014 Jul; 7(4):627-33. PubMed ID: 24874201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
    Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
    Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.
    Burashnikov A; Belardinelli L; Antzelevitch C
    Heart Rhythm; 2015 Apr; 12(4):836-44. PubMed ID: 25546810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.
    Milberg P; Frommeyer G; Ghezelbash S; Rajamani S; Osada N; Razvan R; Belardinelli L; Breithardt G; Eckardt L
    Europace; 2013 May; 15(5):761-9. PubMed ID: 23376977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can inhibition of IKur promote atrial fibrillation?
    Burashnikov A; Antzelevitch C
    Heart Rhythm; 2008 Sep; 5(9):1304-9. PubMed ID: 18774108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates.
    Comtois P; Sakabe M; Vigmond EJ; Munoz M; Texier A; Shiroshita-Takeshita A; Nattel S
    Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1489-504. PubMed ID: 18676686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.
    Burashnikov A; Sicouri S; Di Diego JM; Belardinelli L; Antzelevitch C
    J Am Coll Cardiol; 2010 Oct; 56(15):1216-24. PubMed ID: 20883928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of late sodium channel current block in the management of atrial fibrillation.
    Burashnikov A; Antzelevitch C
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):79-89. PubMed ID: 23108433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy.
    Aguilar M; Nattel S
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):432-40. PubMed ID: 25923324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theoretical possibilities for the development of novel antiarrhythmic drugs.
    Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
    Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.
    Savelieva I; Camm J
    Europace; 2008 Jun; 10(6):647-65. PubMed ID: 18515286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
    Burashnikov A; Di Diego JM; Sicouri S; Ferreiro M; Carlsson L; Antzelevitch C
    Heart Rhythm; 2008 Dec; 5(12):1735-42. PubMed ID: 19084813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic properties of ranolazine: A review of the current evidence.
    Gupta T; Khera S; Kolte D; Aronow WS; Iwai S
    Int J Cardiol; 2015; 187():66-74. PubMed ID: 25828315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.